Vaccination with AstraZeneca continues for people aged 60 years and older As advised by the Health Council of the Netherlands, vaccination with AstraZeneca will be continued for people born in 1960 or before. People under the age of 60 will receive a different vaccine.
Fewer coronavirus infections among people who kept distancing People who follow the advice to stay 1.5 apart from others are less likely to contract the coronavirus SARS-CoV-2.
Coronavirus monitoring in sewage research expanded and extended Since March 2020, RIVM has been working with the water boards in the Netherlands to monitor sewage for traces of the coronavirus SARS-CoV-2. The measurements are an important supplement to other COVID-19 studies.
Fewer cases, higher percentage of positive tests In the week of 31 March to 6 April, 48,186 people in the Netherlands received a positive test result for COVID-19. That is a decrease of 7% compared to the week before.
New hold on vaccination with AstraZeneca for people under 60 years The Ministry of Health, Welfare and Sport (VWS) has decided to stop vaccinating with the COVID-19 vaccine made by AstraZeneca for people under 60 (born in 1961 or later), effectively from now until Wednesday.
People born 1947-1951 invited for COVID-19 vaccination starting 6 April Starting Tuesday 6 April, the first people in the next age group will receive an invitation from RIVM for a COVID-19 vaccination. These people were born in the years from 1947 through 1951.
Single vaccination after COVID-19 infection within the past six months Starting today, people who tested positive for COVID-19 in the past six months can indicate when scheduling a vaccination appointment that they only want one vaccine dose.
Less air pollution from traffic and industry but increased contribution from agriculture International air policy has shown good results in Europe: in the past 35 years the air has become cleaner. Nevertheless air pollution is still an important cause of premature death.
Early detection of work-related health risks in Europe At European level, different methods are used to identify substances and processes that may cause cancer as early as possible, the so-called early warning systems.
Burden of disease and societal costs of work-related cancer in the European Union Yearly approximately 122,600 people in the EU are diagnosed with cancer, caused by past exposure to carcinogenic substances at work.